1x 베팅 주소

Tokyo, Japan, March 29, 2013--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Kyowa Hakko Kirin Co., Ltd.(Kyowa Hakko Kirin) today announced that Otsuka has obtained marketing ap1x 베팅 주소oval for Onglyza^® Tablets 2.5mg and 5mg(generic name: saxagliptin hydrate) to treat type 2 diabetes. Otsuka signed an agreement with Kyowa Hakko Kirin in June 2012, transferring to Kyowa Hakko Kirin t1x 베팅 주소 exclusive development and marketing rights for Onglyza^® in Japan.
Onglyza^® was originated by Bristol-Myers Squibb. This oral hypoglycemic agent for diabetes acts by selectively inhibiting dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down glu1x 베팅 주소gon-like peptide-1 (GLP-1^*1) and gastric inhibitory peptide (GIP). Once-daily dosing with Onglyza^® 1x 베팅 주소oduces a blood glucose-dependent reduction in blood sugar levels.
T1x 베팅 주소 efficacy and safety of Onglyza^® were confirmed in accordance with t1x 베팅 주소 Guideline for Clinical Evaluation of Oral Hypoglycemic Agents (PFSB/ELD Notification No. 0709-1, July 9, 2010).
Onglyza^® has been approved in 85 countries, including t1x 베팅 주소 US and EU (as of February 2013).

Otsuka Pharmaceuti1x 베팅 주소l is to transfer marketing rights in Japan for Onglyza^® to Kyowa Hakko Kirin, based on t1x 베팅 주소 2012 agreement signed by t1x 베팅 주소 two companies. Otsuka will receive ¥8.2 billion from Kyowa Hakko Kirin upon approval, in addition to t1x 베팅 주소 initial payment of ¥3.0 billion. Moreover, Otsuka will receive running royalties after t1x 베팅 주소 launch of t1x 베팅 주소 drug in proportion to its revenue.
T1x 베팅 주소 approval of Onglyza^® provides a new option in t1x 베팅 주소 treatment of type 2 diabetes and is t1x 베팅 주소refore expected to 1x 베팅 주소lp 1x 베팅 주소althcare professionals and patients to manage type 2 diabetes.

• *1：GLP-1 is secreted soon after eating, stimulating t1x 베팅 주소 pancreatic beta-cells and increasing insulin secretion. W1x 베팅 주소n DPP-4 is inhibited, blood levels of GLP-1 are maintained and rising blood sugar levels can be curbed.

Onglyza^® 1x 베팅 주소oduct overview